Allergan’s Mixed R&D News Gives It A Shot In The Eye
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Allergan announced plans to initiate a Phase III clinical trial for its macular degeneration candidate DARPin and FDA approval of a new indication for the eye drug Ozurdex, but FDA also declined to approve Semprana for migraine.